NCT07914972Not yet recruiting
Treatment Pattern and Patient Outcomes Among Stage I-II Unresected NSCLC Patients
iTERESA Study Treatment Pattern and Patient Outcomes Among Stage I-II Unresected NSCLC Patients.
Source: ClinicalTrials.gov · Last updated 4 Nov 2026
Brief summary (registry, in English)
The iTERESA study is a retrospective, cross-sectional, non interventional, multi-country observational HCPs survey designed to characterize real-world management of adult patients with stage I-II unresected NSCLC.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 440 (estimated)
- First submitted
- 28 Oct 2026
- Start date
- 30 Oct 2026
- Primary completion date
- 30 Dec 2026
- Lead sponsor
- AstraZeneca
- Diseases
- Lung cancer
- NCT number
- NCT07914972
What you commit to
- Study type: Observational
- Planned participants: 440
- From 30 Oct 2026 to the primary completion date, 30 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- \- Patients with previous history of cancer
Other
- \- Patients with anaplastic lymphoma kinase mutation (ALK)
- \- Patients without post-diagnosis information
Who the study is looking for
- \- Patient with unresected stage I-II NSCLC
- \- Patient aged 18 years or older at the time of diagnosis
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.